Moderna price target lowered to $200 from $225 at Deutsche Bank

Deutsche Bank lowered the firm’s price target on Moderna to $200 from $225 and keeps a Buy rating on the shares. The analyst updated the firm’s model post the Q4 results. The pathway back to sustainable post-COVID profitability looks less clear given the "collapse" in booster demand and mixed recent flu data complicating the path to regulatory approval, the analyst tells investors in a research note. However, the analyst thinks approval will be granted if pending Northern Hemisphere data shows non-inferiority as is likely.